Connect with us

Hi, what are you looking for?

top
Britain has become the first nation to approve the coronavirus vaccine developed by AstraZeneca and the University of Oxford

World

US hits record daily Covid-19 deaths as world looks to vaccines in 2021

Norman Einspruch, 88, a cardiology patient, receives his first dose of the Pfizer-BioNtech Covid-19 vaccine in Miami, Florida on December 30, 2020 © AFP / Eva Marie UZCATEGUI

Washington, United States, Dec 29 – The US logged its highest ever daily death toll from the coronavirus Wednesday as the world prepares to turn the page on a grim year defined by the pandemic, with much of the globe united in one hope for 2021: that a slew of new vaccines will stamp out Covid-19.

New Year’s Eve marks one year since the World Health Organization first mentioned a mysterious pneumonia in China later identified as Covid-19, which went on in 2020 to kill more than 1.79 million people and devastate the global economy in unprecedented ways.

In the world’s worst-hit country, the US, the numbers keep climbing: On Wednesday more than 3,900 people died of Covid-19, a new record, bringing the toll since the pandemic began to more than 19.7 million infections and 341,000 lives lost.

And experts believe the worst is yet to come, as US healthcare workers brace for a surge in cases after major holiday gatherings.

But international efforts helped develop vaccines in record time. On Wednesday Britain approved a lower-cost vaccine developed by the University of Oxford and drug firm AstraZeneca, making it the third jab to win approval in the Western world, after the Pfizer-BioNTech and Moderna vaccines.

Britain, hard hit by a worrisome new strain of the virus and now divorced from the European Union due to Brexit, will “move to vaccinate as many people as quickly as possible,” tweeted British Prime Minister Boris Johnson.

Unlike the Pfizer-BioNTech and Moderna vaccines, the one from AstraZeneca and Oxford does not need to be stored at very low temperatures.

Paramedics move a patient suspected of having Covid-19 at a hospital in Mexico City, on December 30, 2020 © AFP / PEDRO PARDO

It can be kept, transported and handled in normal refrigerated conditions, making it easier and cheaper to administer, which is particularly important for less wealthy nations.

Hours later, Argentina became the second nation to approve the vaccine, and was soon followed by El Salvador. Argentina and Mexico have agreements to distribute the vaccine in Latin America.

But the United States and European Union indicated that they would not soon follow suit.

Moncef Slaoui, the chief advisor to Operation Warp Speed, the military-led US vaccine effort, told reporters that he expected approval “sometime in early April.”

Advertisement. Scroll to continue reading.

He did not fault Britain’s health agency but said the United States was following its own trials and evaluations.

He also voiced hope that Johnson & Johnson’s Janssen vaccine — which, in contrast to initially approved jabs, requires just one dose — could be ready for approval in the United States in the first half of February.

– Russian, Chinese vaccines –

Russia and China also claim to have developed Covid-19 vaccines, and have already started administering them.

Chinese pharma giant Sinopharm on Wednesday said Phase 3 trials of its candidate had shown 79 percent effectiveness, short of the more than 90 percent achieved by Pfizer-BioNTech and Moderna. The firm has applied to China’s drug regulator for approval.

Vaccine effectiveness © AFP / Alain BOMMENEL

But Beijing has struggled to gain international trust for its vaccines, hindered by a lack of data transparency as well as criticism over its handling of the initial outbreak of the virus in the central Chinese city of Wuhan.

Earlier this week, a Chinese court handed a four-year prison term to a citizen journalist who provided rare unvarnished reports from Wuhan of the early days of the pandemic.

A new official Chinese study said that infections in Wuhan may have been 10 times higher than official figures suggest.

China’s Centre for Disease Control found that 4.4 percent of the city’s 11 million people had developed antibodies against the virus causing Covid-19 by April — meaning around 480,000 infections, far above the official tally of 50,000 cases to date.

– New variant worries –

Advertisement. Scroll to continue reading.

Even as vaccinations ramp up in Europe and North America, global infections have surged to more than 82 million.

Germany has banned New Year’s Eve gatherings © AFP / Odd ANDERSEN

Germany, which had handled the first coronavirus wave relatively well, has been hit hard by the second.

It logged more than 1,000 daily deaths for the first time, authorities said Wednesday, as Chancellor Angela Merkel warned that the country’s “difficult times” were going to last “for a good while yet.”

Germany is under a partial lockdown, with most shops closed along with schools, restaurants, and cultural and leisure facilities, with senior politicians already pressing to extend the closures beyond the current January 10 end-date.

Experts believe the new variant in nearby Britain could be more contagious, contributing to record daily caseloads in England and sparking fear as it quickly proliferates.

Indian authorities were trying Wednesday to track down tens of thousands of recent arrivals from Britain as cases of the new variant more than doubled in 24 hours.

California became the second US state to detect the variant — after Colorado — with a 30-year-old San Diego man testing positive.

Top US government scientist Anthony Fauci said he was “not surprised” by the variant’s spread and warned the nation “likely will be seeing reports from other states.”

Ireland also announced the tightening of coronavirus restrictions for at least a month including the closing of non-essential retail and gyms.

“We will do what we need to do to suppress the virus,” Prime Minister Micheal Martin said in a televised address. “It is now growing exponentially.”

Advertisement. Scroll to continue reading.

burs-st/bfm

About The Author

Advertisement

More on Capital News